Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 395 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Immunodeficiency Syndromes Clear all
Completed Not applicable Interventional Results available

An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

NCT05709860
View directory record Official record
Conditions
HIV Infections, Electronic Health Record, Primary Health Care
Interventions
EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

EZN-2279 in Patients With ADA-SCID

NCT01420627
View directory record Official record
Conditions
ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
Interventions
EZN-2279, Adagen
Biological
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

NCT03266627
View directory record Official record
Conditions
Adenovirus, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 19, 2026, 10:43 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

NCT06851767
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions
Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells
Genetic · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrated Health Services (IHS): A Structural Intervention to Improve HIV/STI Screening and PrEP Navigation in Primary Care

NCT07446764
View directory record Official record
Conditions
HIV, STDs
Interventions
Integrated HIV/STI Testing and PrEP Navigation Model
Behavioral
Lead sponsor
My Brother's Keeper, Inc.
Other
Eligibility
18 Years to 45 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Ridgeland, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide

NCT03188419
View directory record Official record
Conditions
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

NCT00152100
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Stem cell transplant, Filgrastim, Alemtuzumab, Miltenyi CliniMACS
Procedure · Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 2 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

NCT01359969
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
rhC1INH
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
2 Years to 13 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Online HIV Prevention for Young Male Couples

NCT03284541
View directory record Official record
Conditions
Hiv, Chlamydia, Gonorrhea
Interventions
2GETHER, Existing Public Health Practice
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

NCT04414046
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Metabolic Disease
Interventions
Haploidentical Hematopoietic Cell Transplantation
Biological
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings

NCT03092596
View directory record Official record
Conditions
Substance Abuse
Interventions
Patient-administered screening tool, Patient health navigator-administered screening tool, Patient health navigator-assisted linkage to treatment
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

NCT00695279
View directory record Official record
Conditions
Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Interventions
Venipuncture
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)

NCT00023010
View directory record Official record
Conditions
Leukocyte Adhesion Deficiency Syndrome
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

NCT01095497
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CINRYZE
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 19, 2026, 10:43 PM EDT
Withdrawn No phase listed Observational

A Study of Patients Who Recently Have Been Infected With HIV

NCT00006415
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Open Contest and Neuro-influence Experiment to Develop and Evaluate PrEP Promotion Messages for High Risk Men

NCT04166851
View directory record Official record
Conditions
HIV/AIDS
Interventions
PrEP campaign messages developed via open contest, PrEP campaign messages developed via social marketing approach
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

NCT00074581
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 19, 2026, 10:43 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 19, 2026, 10:43 PM EDT
Terminated Not applicable Interventional

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054
View directory record Official record
Conditions
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
Up to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03513328
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

NCT02572401
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Sexually Transmitted Disease (STD)
Interventions
STAND HIV Risk Reduction Intervention, Text Messaging Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 19, 2026, 10:43 PM EDT